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Sleep  apnea  is frequently  observed  in  patients  with  heart  failure  (HF).  In general,  sleep  apnea  consists
of two  types:  obstructive  and  central  sleep  apnea  (OSA  and  CSA,  respectively).  OSA results  from  upper
airway collapse,  whereas  CSA  arises  from  reductions  in  central  respiratory  drive. In patients  with  OSA,
blood  pressure  is frequently  elevated  as  a  result  of sympathetic  nervous  system  overactivation.  The
generation  of exaggerated  negative  intrathoracic  pressure  during  obstructive  apneas  further  increases  left
ventricular  (LV)  afterload,  reduces  cardiac  output,  and  may  promote  the  progression  of HF.  Intermittent
hypoxia  and  post-apneic  reoxygenation  cause  vascular  endothelial  damage  and possibly  atherosclerosis
and  consequently  coronary  artery  disease  and  ischemic  cardiomyopathy.  CSA  is  also  characterized  by
apnea,  hypoxia,  and  increased  sympathetic  nervous  activity  and,  when  present  in HF, is  associated  with
increased  risk  of death.  In patients  with  HF,  abolition  of  coexisting  OSA  by continuous  positive  airwayentilation pressure  (CPAP)  improves  LV  function  and  may  contribute  to the  improvement  of long-term  outcomes.
Although  treatment  options  of  CSA  vary  compared  with  OSA  treatment,  CPAP  and  other  types  of  positive
airway  ventilation  improve  LV  function  and  may  be  a promising  adjunctive  therapy  for HF patients  with
CSA.  Since  HF remains  one  of  the  major  causes  of  mortality  in  the  industrialized  countries,  the signiﬁcance
of  identifying  and  managing  sleep  apnea  should  be  more  emphasized  to  prevent  the  development  or
progression  of HF.© 2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
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. Introduction
In patients with heart failure (HF), two types of sleep apnea can
e seen: obstructive and central sleep apnea (OSA and CSA, respec-
ively). OSA results from upper airway collapse, whereas CSA arises
rom reductions in central respiratory drive. During OSA, the respi-
atory effort generated against the narrowed upper airway causes
he rib cage and abdomen to distort and move out of phase. In
ontrast, in CSA, respiratory movements are absent or attenuated,
ut in phase. In HF patients, CSA usually occurs as Cheyne–Stokes
espiration (CSR) which is a form of periodic breathing character-
zed by a crescendo–decrescendo pattern of breathing followed by
entral apnea or hypopnea. Since this review aims to highlight the
athophysiology and therapies of sleep apnea in HF due to left ven-
ricular (LV) systolic dysfunction, the terms “CSA” and “HF” are used
s synonymous with CSR and HF due to LV systolic dysfunction,
espectively, unless indicated otherwise.
. Risk factors and pathogenesis of sleep apnea
OSA is 2–3 times more common in men  than in women, and
n elderly than in young both in the general population and in
atients with HF [1]. Obesity is regarded as one of the major risk fac-
ors for OSA. Nevertheless, OSA can occur in individuals of normal
eight in whom other factors can contribute to pharyngeal col-
apsibility, such as macroglossia, and adenotonsillar hypertrophy.
nomalies of craniofacial structure, such as retrognathia, which
an displace the tongue backward and narrow the pharynx, can be
mportant in non-obese Asians. Nasal obstruction can also increase
he risk for developing OSA, possibly by causing increased collapsi-
ility or airway narrowing in the pharynx as a result of increased
irway resistance upstream from the collapsible portion on inspi-
ation. Hereditary factors and respiratory control system instability
ay  also contribute to the pathogenesis of OSA, but these remain
ontroversial. Previous studies showed that topical (to the pha-
yngeal mucosa) administration of vasomotor agents can alter the
haryngeal resistance [2]. These observations suggest that ﬂuid
ccumulation in nuchal and peripharyngeal soft tissues may  cause
haryngeal narrowing and increase the likelihood of pharyngeal
cclusion in patients predisposed to OSA. In addition, Shepard et al.
3] proposed that ﬂuid displacement from the lower extremities
o the upper body might play a role in narrowing the pharynx in
atients with OSA. Dependent ﬂuid accumulation in the legs while
pright during the day could shift rostrally into the neck when
ecumbent during sleep. Such ﬂuid displacement might cause dis-
ension of the neck veins and/or edema of the peripharyngeal soft
issue that increases tissue pressure, predisposing to pharyngeal
bstruction. Yumino et al. [4] demonstrated that the greater the
mount of ﬂuid displaced spontaneously from the legs overnight,
he greater the overnight increase in neck circumference and the
everity of OSA as assessed by frequency of apnea and hypopnea per
our of sleep (i.e. apnea–hypopnea index, AHI) in HF patients with
SA. Fluid volume displaced from the legs was directly proportional
o the time spent sitting during the day.
CSA is also 2–3 times more common in men  than in women  [1].
eing elderly, male, with low PaCO2, coexistence of atrial ﬁbrilla-
ion, and use of diuretics were reported as independent predictors
f CSA in HF patients [1].  CSA appears to arise secondary to HF
nd occurs when PaCO2 falls below apnea threshold. In general, HF
atients tend to hyperventilate chronically owing to stimulation of . . .  . . . . .  .  . . . . . .  .  . . . . . .  .  . . . .  . .  .  . . . . . . .  . .  . . . . .  .  . . . . . . .  .  .  . .  . . . .  . . . . . .  . .  . .  . . . .  84
pulmonary vagal irritant receptors by pulmonary congestion and
to increased central and peripheral chemosensitivity (Fig. 1) [5].
When PaCO2 falls below apnea threshold because of increase in
the apnea threshold during transition from wakefulness to sleep or
acute increase in ventilation which is triggered by a spontaneous
arousal, the CSA ensues [5].  Apnea persists until PaCO2 raises above
apnea threshold then ventilation will resume and ventilatory over-
shoot occurs and PaCO2 will go down below the apnea threshold
in association with arousal during ventilatory phase and increased
chemosensitivity which is characteristic of HF patients with CSA.
The length of the ventilatory phase following CSA is directly propor-
tional to the lung to peripheral chemoreceptor circulation time and
inversely proportional to cardiac output, reﬂecting delayed trans-
mission of change in arterial blood gas tensions from the lungs to
the chemoreceptor in association with impaired cardiac output in
HF patients. This could also contribute to the pathogenesis of CSA
with CSR pattern by facilitating ventilatory overshoot and under-
shoot. Thus, once triggered, the pattern of CSR will be sustained by
the combination of increased respiratory chemoreceptor drive, pul-
monary congestion, arousals, and apnea-induced hypoxia, which
cause oscillations in PaCO2 above and below the apnea threshold
[5].
As well as OSA, the degree of rostral ﬂuid displacement from
the legs overnight is directly related to the severity of CSA, but is
inversely proportional to PaCO2 during sleep and in men with HF
[4].  It is therefore likely that a portion of this ﬂuid was redistributed
into the lungs and caused pulmonary congestion that stimulates
pulmonary vagal irritant receptors to elicit reﬂex hyperventilation.
In both OSA and CSA patients, the concept of nocturnal rostral
ﬂuid shift which is suggested as contributing to the pathogenesis
of both OSA and CSA was also supported by a recent report which
showed that in patients with HF, there was a signiﬁcant positive
correlation between the AHI and amount of dietary sodium intake
[6].
3. Adverse effect of sleep apnea on cardiac function
3.1. Effect of disrupted sleep
In healthy subjects, metabolic rate, sympathetic nervous activ-
ity (SNA), blood pressure (BP), and heart rate (HR) fall and cardiac
vagal activity increases during non-rapid eye movement (non-
REM) sleep, which constitutes approximately 85% of total sleep
time. Thus, in general, sleep is a state of cardiovascular relaxation.
On the other hand, intermittent surges in SNA, BP, and HR occur in
REM sleep, but in general, REM comprises only 15% of total sleep
time, and average BP and HR remain below waking levels. Thus,
sleep is generally a state of cardiovascular quiescence. Sleep apnea
interrupts such cardiovascular quiescence with potential adverse
consequences, such that the sufferer may  not enjoy the restorative
effect of sleep.
3.2. Effects of obstructive sleep apnea
3.2.1. Direct effects on cardiac function
A unique feature of OSA is the generation of exaggerated neg-ative intrathoracic pressure. During obstructive apneas, negative
inspiratory intrathoracic pressure generated against the occluded
pharynx increases LV transmural pressure (i.e. intra-cardiac minus
intra-thoracic pressure), and hence LV afterload. It also increases
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enous return, augmenting right ventricular (RV) preload, while
SA-induced hypoxic pulmonary vasoconstriction increases RV
fterload. Consequent RV distension and leftward septal displace-
ent during diastole impair LV ﬁlling. The combination of increased
V afterload and diminished LV preload during obstructive apneas
auses a progressive reduction in stroke volume and cardiac out-
ut [7].  OSA-induced hypoxia might also directly impair cardiac
unction [7].  Autonomic cardiovascular dysregulation, character-
zed by elevated SNA and parasympathetic withdrawal, is another
allmark of OSA. All of apnea-induced intermittent hypoxia and
O2 retention, the absence of breathing during apnea, barorecep-
or reﬂex stimulated by reductions in stroke volume and cardiac
utput, and arousal from sleep at apnea termination also augment
NA [7]. Importantly, the adverse effects of OSA on the autonomic
ervous system are not conﬁned to sleep but may  persist into
akefulness [7].  The mechanism of such daytime carry over effects
emains unclear. Repetitive apneas expose the cardiovascular sys-
em to exaggerated negative intrathoracic pressure, intermittent
ypoxia, surges in SNA and frequent awakenings. Over time, such
tresses may  directly contribute to development or progression of
F.
.3. Indirect effect predisposing to heart failure
Several experimental studies suggested that OSA can raise BP.
ndeed, it was shown that there is an association between OSA and
ncidence of hypertension [8]. Although two other recent studies
9,10] failed to show signiﬁcant independent association between
SA and risk of hypertension, in patients with OSA, physiological
ipping in nighttime BP is often lacking [11] in association with
octurnal sympathetic activation and consequent increase in BP.
oreover, there is evidence that indicates the association between
rug-resistant hypertension and OSA. Thus, hypertension which is
n important factor for LV hypertrophy and dysfunction, is likely
n intermediate step between OSA and HF.
Intermittent apnea-related hypoxia and post-apneic reoxygena-
ion can induce oxidative stress with production of reactive oxygenal sleep apnea; LVEDP, left ventricular end diastolic pressure.
species which diminishes bioavailability of nitric oxide, and acti-
vation of inﬂammatory mediators possibly through the activation
of nuclear transcriptional factors [12], that are capable of impair-
ing vascular endothelial function (Fig. 2). Indeed, patients with
OSA have low plasma nitrite concentrations and high levels of
oxidative stress markers [12]. In addition, patients with OSA have
greater blood levels of several inﬂammatory mediators [12]. How-
ever, although it remains under debate, most of them are reversible
by continuous positive airway pressure (CPAP) therapy for OSA
[12]. More recently, it was reported that blood level of pentraxin-3
which is regarded as a more speciﬁc marker of vascular inﬂamma-
tion than C-reactive protein was  greater in patients with moderate
to severe OSA compared with subjects without OSA and 1 month of
CPAP therapy signiﬁcantly decreased pentraxin-3 level in associa-
tion with usage of CPAP [13]. Combined with increased sympathetic
vasoconstrictor activity, all these could predispose to advanced
endothelial dysfunction, and moreover have the potential to accel-
erate atherogenesis. Randomized trials demonstrated that CPAP
therapy for OSA resulted in a signiﬁcant improvement in endothe-
lial function [14], indicating a cause and effect relationship between
OSA and endothelial dysfunction. It was  also reported that patients
with OSA had impaired myocardial perfusion but that was  signiﬁ-
cantly improved by alleviation of OSA with CPAP [15]. Furthermore,
patients with OSA display greater signs of early atherosclerosis,
including increased carotid intima-media thickness and increased
arterial stiffness [13,16]. A randomized trial demonstrated that
4 months of CPAP therapy to OSA reduced carotid intima-media
thickness and arterial stiffness [17]. Recent observational studies
showed that short-term CPAP therapy can reduce arterial stiffness
parameters in association with reduction of SNA and that long-term
(>1 year) CPAP therapy can retard progression of arterial stiffness
[18]. As a consequence of such OSA-related atherogenesis, patients
with OSA are likely to have coronary artery disease (CAD) and
ischemic cardiomyopathy, although a recent longitudinal analy-
sis of the Sleep Heart Health Study including 1927 men and 2495
women without any cardiovascular diseases at the baseline (mean
follow-up duration, 8.7 years) showed that after adjustment for
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ther risk factors, presence of OSA at baseline was a signiﬁcant pre-
ictor of incident CAD only in men  <70 years of age (adjusted hazard
atio [HR], 1.10; 95%CI, 1.00–1.21 in each 10-unit AHI increase, and
djusted HR, 1.68; 95%CI, 1.02–2.76 for those with AHI ≥ 30 com-
ared with those with AHI < 5) but not in older men  or in women  at
ny age [19]. Nevertheless, once severe CAD such as myocardial
nfarction occurred, OSA-related intermittent hypoxia, negative
ntrathoracic pressure, and hypertension can provoke myocardial
xygen demand-supply mismatch and may  cause LV dysfunction
nd HF by impairing recovery of LV systolic function following
yocardial infarction [20].
A longitudinal analysis of the Sleep Heart Health Study [19]
howed that after adjustment for other risk factors, presence of
SA at baseline was a signiﬁcant predictor of incident HF in men
adjusted HR, 1.13; 95%CI, 1.02–1.26 in each 10-unit AHI increase).
ince this relationship was not observed in women, we still need
urther studies including not only population-based study but also
andomized study investigating effect of OSA treatment on pre-
enting incident HF.
.4. Effects of central sleep apnea on cardiac function
Although CSA appears to arise secondary to HF, once initiated it
ay  participate in a pathophysiologic vicious cycle that contributes
o deterioration in cardiac function.
However, it is still under debate whether CSA is simply a marker
f severely impaired cardiac function with pulmonary conges-
ion, or whether CSA exerts independent pathologic effects on the
mpairment of cardiac function. Nevertheless, there is evidence that
SA may  have detrimental physiologic effects on cardiac function.
As well as OSA, during central apnea, the absence of breath-
ng eliminates reﬂex inhibition of central sympathetic nerve trafﬁc
rising from pulmonary stretch receptors, that are activated dur-
ng normal breathing and as a result, SNA is enhanced. This effect
ummates with apnea-related intermittent hypoxia and CO2 reten-
ion and with arousals to cause cyclical surges in SNA and cause aia induced factor-1; NFB, nuclear factor B; NO, nitric oxide; OSA, obstructive
generalized increase in overnight SNA [21]. In addition, the adverse
effects of CSA on SNA are not conﬁned to sleep but may persist into
wakefulness [22]. Indeed, ventricular arrhythmias are more com-
mon in HF patients with CSA than those without it in association
with increased SNA [23]. On the other hand, the role of intermit-
tent hypoxia and its related mechanisms such as oxidative stress
and inﬂammation in CSA remains unclear in contrast to OSA.
4. Sleep apnea in heart failure
4.1. Clinical features
Key clinical features of OSA include coexisting obesity and
excessive daytime sleepiness (EDS). However, some OSA patients
do not have any such symptoms and signs despite quite severe dis-
order. Although clinical features of OSA in patients with HF share
several features with OSA in the general population, they differ in
some important aspects. Although obesity is also associated with
OSA in patients with HF [1],  a larger population are non-obese than
in the general population [24]. Therefore, in the HF population, the
presence of obesity is an insensitive factor for predicting the pres-
ence of OSA. Hence, in the HF population, factors other than obesity
must play a more important role in the pathogenesis of OSA than
in the general population. One such factor may be ﬂuid retention
in the legs and rostral ﬂuid shift from the legs to the upper body
as mentioned earlier. In contrast to the general population, most
patients with HF who have OSA do not complain of EDS and have
an Epworth Sleepiness Scale (ESS) score within normal limits (gen-
erally <11) [24], indicating that a complaint or symptoms of EDS
are insensitive indices of the presence of OSA in the HF population.
A recent study suggests that such lack of subjective sleepiness in
HF patients with OSA is associated with HF-related increase in the
SNA [25]. It was also reported that obesity is not a good indicator
of CSA [1].  Similar to OSA patients with HF, most CSA patients do
not complain of EDS [26].
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.2. Epidemiology
As compared with the general population, the prevalence of OSA
s generally higher in HF populations. For instance, prevalence of
SA in HF is 12–26% at an AHI cut-off of ≥15 [1,26].  A high frequency
f CSA in patients with HF has been widely noted [1,26].  CSA deﬁned
y an AHI ≥ 15 with >50% central events was observed in 21–37%
f HF patients [1,26].
In patients with HF, adverse effects of sleep apnea described
arlier may  promote further progression of cardiac dysfunction
nd worsen prognosis. Indeed, a recent observational study suggest
hat the presence of untreated OSA (deﬁned as AHI ≥ 15) among HF
atients is associated with increased mortality compared to those
ith an AHI < 15 even after adjustment for other confounding fac-
ors [27]. A number of studies reported that CSA is a signiﬁcant
ndependent predictor of mortality in HF patients with HF [5].  How-
ver, it remains unclear whether there is a direct cause and effect
elationship between sleep apnea and risk for morbidity and mor-
ality of HF.
. Treatment for patients with heart failure and sleep apnea
.1. Effect of heart failure treatment on sleep apnea
There are several interventions for HF whose effects on sleep
pnea have been tested. Considering the issue of ﬂuid retention
nd rostral ﬂuid shift in patients with HF [4],  decreased intravascu-
ar volume and attenuated venous congestion caused by treatment
f HF may  potentiate the reduction of both OSA and CSA severities.
n particular, ﬁrst-line therapy for CSA patients should be optimiza-
ion of HF treatment which can cause a reduction of systemic and
ulmonary congestion since CSA is largely a consequence of HF and
ulmonary congestion.
Bucca et al. reported that administration of furosemide and
pironolactone for 3 days induced signiﬁcant increase in the upper
irway caliber and reduction in AHI (from 75 to 57, p < 0.001) in
atients with severe OSA and diastolic HF [28]. Ueno and colleagues
emonstrated that after 4 months of exercise training, as a speciﬁc
reatment for HF, AHI signiﬁcantly decreased in HF patients with
SA but not in those patients with HF and CSA [29]. In another
tudy, 6 months of exercise training caused 64% reduction in AHI in
F patients with CSA [30]. It was reported that cardiac resynchro-
ization therapy (CRT) induced reduction in the AHI in HF patients
ith OSA although a recent meta-analysis suggested a negative
ffect of CRT on OSA [31]. Similarly, CRT was accompanied by allevi-
tion of CSA in association with an improvement in cardiac function
31]. Heart transplantation can also alleviate CSA in patients with
F [32]. Thus, optimizing HF therapy can stabilize ventilatory con-
rol and attenuate both OSA and CSA severities. However, none of
hem was a randomized controlled study.
.2. Effect of sleep apnea treatment on heart failure
.2.1. Treatment for obstructive sleep apnea
The standard treatment for OSA in patients with HF is CPAP.
PAP splints the pharynx and maintains its patency, thereby pre-
enting apneas and hypopneas and may  have beneﬁcial positive
irway pressure effects on HF independent from treating OSA. In
eneral population, oral appliances or surgery are less effective
han CPAP. It remains unclear whether treating OSA using these
ptions is beneﬁcial or not in patients with HF. Weight loss has
een shown to decrease the AHI in general OSA population. How-
ver, as mentioned earlier, in the HF population, obesity must play
 less important role in the pathogenesis of OSA than in the gen-
ral population. In addition, it takes a long time to lose clinicallyogy 60 (2012) 78–85
signiﬁcant weight and it is quite difﬁcult to sustain achieved weight
loss especially in patients with HF.
As an OSA treatment, in addition to the alleviation of OSA, one
night application of CPAP caused abolition of negative intrathoracic
pressure swings and reductions in nocturnal BP, that caused a dra-
matic reduction in LV afterload that was  accompanied by a decrease
in HR [33]. Randomized trials of ﬁxed-pressure CPAP involving HF
patients with OSA demonstrated an improvement in LV systolic
function in association with reductions in BP, HR, and SNA [34,35].
In terms of long-term clinical outcome, there are two observational
studies. In a study involving 218 HF patients among 51 patients with
OSA and an AHI ≥15, there was a trend to a lower mortality rate
in the 14 who  accepted CPAP therapy than in the 37 who did not
(mortality rate of 0 versus 7.2 per 100 person-years, p = 0.07) over
mean and maximum follow up periods of 2.9 and 7.3 years, respec-
tively [27]. In another study among 88 HF patients with moderate
to severe OSA, 65 CPAP-treated patients had signiﬁcantly greater
hospitalization-free survival than 23 untreated patients over mean
and maximum follow up periods of 2.1 and 4.8 years, respec-
tively [36]. Furthermore, among the 65 CPAP-treated patients, the
hospitalization-free survival rate was signiﬁcantly higher in more
compliant group (N = 32), whose average nightly usage was more
than the median level (4.9 h), than in the less compliant group
(N = 33) whose average nightly usage was  4.9 h or less.
In the American Heart Association/American College of Car-
diology Foundation scientiﬁc statement on sleep apnea and
cardiovascular disease [37], treatment of OSA in HF patients is con-
sidered as being investigational because the effect of OSA treatment
by CPAP in HF patients has not yet been clariﬁed in randomized tri-
als, and because most HF patients with OSA do not complain of
EDS and therefore, indications for treating OSA in such patients
have not been clearly deﬁned. As mentioned earlier, a recent
study showed an inverse relationship between EDS  and SNA in HF
patients with OSA [25]. This ﬁnding suggests, paradoxically, that
among HF patients with OSA, those with the less daytime sleepi-
ness may  have greater potential for beneﬁt from therapy of OSA
than those with more daytime sleepiness. This possibility warrants
further investigation.
5.3. Treatment for central sleep apnea
There are several options in CSA treatment [38,39]. Theophilline
which stimulates central respiratory drive and augments cardiac
contractility, and raising PaCO2 above the apneic threshold either
via inhaled CO2 or addition of dead space were effective to reduce
the AHI or abolish CSA instantaneously [38,39].  However, both
options are no longer used for this purpose because theophilline
may  increase the incidence of cardiac arrhythmias and sudden
death, and because raising PaCO2 may  cause adverse effects by
enhancing SNA [38]. A recent study which reported the effect of
real-time dynamic carbon dioxide administration on CSA [40] may
be a hint for minimizing such adverse effects. Acetazolamide can
reduce the AHI possibly by the stimulation of respiration via caus-
ing metabolic acidosis [38,39]. Recently, two groups reported that
one night application of transvenous phrenic nerve stimulation sig-
niﬁcantly reduced AHI [41,42]. However, their long-term safety and
effects on cardiovascular outcomes remains unclear.
Small short-term randomized trials have demonstrated that
nocturnal oxygen causes approximately 50% reductions in the AHI
in HF patients with CSA [38,39]. In addition to such AHI reductions,
supplemental oxygen reduced overnight urinary norepinephrine
excretion, and improved peak oxygen consumption and ventila-
tory efﬁciency [38,39]. A Japanese group found improvement in
quality-of-life in by 3- and 13-month nocturnal oxygen despite
no improvement in cardiac event rate [39]. Therefore, there is no
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Table  1
Randomized controlled trials investigating effect of ASV on LV function.
Author, year Study design N Duration (months) Type of SDB Baseline Device usage Changes
AHI EF AHI  EF
Pepperell
(2003)
RCT
Subtherapeutic 15 1 CSA 17.7 35.7 3.9 −3.0 0.5
Therapeutic 15 21.9 36.5 5.0 −16.5 1.8
Philippe
(2006)
RCT
CPAP 13 6 CSA 40.5  30 4.2 −20 −2
ASV  12 47.0 29 5.8 −45 7
Fietze
(2008)
RCT
Bi-level PAP 15 1.5 CSA 34.9 25.5 4.8* −18.5 5.6
ASV 15 31.7 24.6 −20.5 1.9
Kasai
(2010)
RCT
CPAP 15 3 CSA+OSA 38.6  36.0 4.4 −23.2 1.9
ASV  16 36.3 35.7 5.2 −35.4 9.1
Randerath
(2012)
RCT
CPAP 34 12 CSA+OSA 41  43 4.3 −24 4.9
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HI, apnea–hypopnea index; ASV, adaptive-servo ventilation; bi-level PAP, bi-lev
jection fraction; LV, left ventricular; O, obstructive; RCT, randomized control trial;
onsistent evidence that it improves cardiovascular function or
linical outcomes by supplemental oxygen.
Since HF patients with CSA are associated with increased LV
lling pressures, CPAP has been applied to them to improve hemo-
ynamics. However, the effects of CPAP on CSA have not been
onsistent. This is probably due to differences in how it is applied.
f CPAP was applied acutely and at low pressure (i.e. 5–7.5 cm H2O),
SA was not alleviated [38]. On the other hand, if CPAP were grad-
ally initiated with pressures of 8–12.5 cm H2O, the AHI reduced
y >50% [38]. Furthermore, if CPAP was titrated gradually, CSA was
lleviated in association with an increase in PaCO2, reduction in
NA, and improvements in cardiac functions including increases in
V ejection fraction (LVEF) [38]. In one small-randomized trial in HF
atients with and without CSA [43], although CPAP had no effect
n either LVEF or the composite of mortality and cardiac trans-
lantation in those without CSA. In those with CSA, CPAP improved
VEF at 3 months and revealed a trend toward a reduced event rate
p = 0.059, the median follow-up period, 2.2 years). In particular,
 sub-group of patients who were compliant with CPAP revealed
 signiﬁcant reduction in the event rate (p = 0.017). The Canadian
ontinuous Positive Airway Pressure for Treatment of Central Sleep
pnea in Heart Failure (CANPAP) trial sought to determine whether
PAP would improve CSA, morbidity, mortality, and cardiovascular
unction in HF patients with CSA receiving contemporary medical
herapy for HF [44]. The CANPAP trial which included 258 patients
ith HF and CSA (130 in a control group and 128 in a CPAP-treated
roup) reproduced previous ﬁndings that CPAP attenuates CSA,
mproves LVEF, and lowers SNA. However, there were no signiﬁ-
ant differences in transplant-free survival between the two groups
mean follow-up duration, 2-years). However, since reversal of CSA
tself appears to be one means by which CPAP could improve car-
iovascular outcome [43], and since it was suggested that there are
ome HF patients whose CSA cannot be attenuated by CPAP [39],
ost hoc analysis of the CANPAP trial was carried out [45]. Post
oc analysis of the CANPAP trial suggests that patients whose AHI
educed below 15 by CPAP at 3 months have a signiﬁcantly better
ransplant-free survival as compared with control groups. Results
f the CANPAP trial do not support routine use of CPAP for HF, post
oc analysis implies potentials of the effective suppression of CSA
i.e. AHI < 15).In this perspective, two newer types of noninvasive positive
irway pressure (PAP) which can more effectively suppress CSA
han CPAP have been in focus. Bi-level PAP provided two differ-
nt levels on PAP in inspiratory and expiratory phases with a47 47 5.2 −36 −1.9
itive airway pressure; C, central; CPAP, continuous positive airway pressure; EF,
eep apnea; SDB, sleep-disordered breathing.
back-up ventilation. Several studies including ours suggested ben-
eﬁcial effects of bi-level PAP on CSA and cardiac function [38,39].
However, compared with bi-level PAP, the effects of CSA suppres-
sion are greater in a newer PAP device, adaptive or auto-servo
ventilation (ASV). Thus, ASV is now more focused rather than
bi-level PAP. Randomized studies in which effects of ASV on
cardiac function were investigated are summarized in Table 1. Pep-
perell et al. [46] showed that nocturnal urinary metadrenaline and
daytime B-type natriuretic peptide concentrations were reduced
signiﬁcantly more by therapeutic than sub-therapeutic ASV. Two
studies showed that as compared with CPAP, ASV had greater
effects on improvement in cardiac functions in HF patients with
predominant CSA [47] and those with coexisting OSA and CSA [48].
On the other hand, Fietze et al. [49] showed that treatment of CSA
with bi-level PAP improved LVEF more than that with ASV although
the difference in the degree of improvement between two  PAPs was
not signiﬁcant. More recently, Randerath et al. reported the long-
term effect of ASV on cardiac function in patients with HF and CSA
[50]. They found signiﬁcantly better improvement in B-type natri-
uretic peptide level but no differences in LV function and exercise
performance. However, this study included HF patients with pre-
served LV systolic function in addition to those with impaired LV
systolic function. Thus, results of this study should be interpreted
with caution. It is premature to recommend ASV as a routine use for
CSA in HF patients because large-scale, long-term randomized trials
which investigate effects of ASV on cardiovascular morbidity and
mortality are lacking. Among patients with HF and CSA, only CPAP
has been shown to have a potential to improve long-term cardio-
vascular outcomes as long as CSA has been effectively suppressed
[45]. Therefore, in HF patients with CSA, CPAP should be tried ﬁrst
and then, if the AHI ≥ 15 even on CPAP, ASV should be considered.
Two ongoing large-scale randomized trials investigating the effect
of ASV in HF patients with CSA on long-term cardiovascular morbid-
ity and mortality will provide further information for CSA treatment
strategy.
6. Conclusions
OSA has adverse effects on cardiac function and could be asso-
ciated with incidence and progression of HF. CSA may  worsen
cardiac function in patients with HF. Data from observational stud-
ies strongly suggest relationships between sleep apnea including
both OSA and CSA, and cardiovascular morbidity and mortality.
Although most of the data are not supported by randomized or
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